30 closest matches · ranked by relevance
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Breast Cancer · Metastatic Breast Carcinoma · Invasive Breast Carcinoma
Primary: Number of Participants With Reduction in CTCs Following High-dose Chemotherapy With Purged Autologous Stem Cell Products — 9 participants
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Lung Cancer
Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Breast Cancer · Breast Neoplasms, Male · Carcinoma, Ductal
Primary: Overall Tumor Response — 1; 8; 14; 9 participants
First or Second Line HER2-negative Breast Cancer · Metastatic Disease Without Bone Metastasis
Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants
Breast Cancer, Metastatic
Primary: Overall Survival — 74 percentage of participants
Breast Cancer
Primary: Objective Response Rate — 0.09 proportion of participants
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Ovarian Cancer Stage IIIC · Ovarian Cancer Stage IV
Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309
Non-small Cell Lung Cancer
Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
Neoplasms, Metastatic
Primary: Percentage of Curatively Treated Patients With Progression-free Survival — 16 percentage of participants
Eyelid Sebaceous Gland Carcinoma
Primary: Sentinel Lymph Node Positivity — 2 Participants
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Lung Cancer · Solid Tumor (Not Breast or Prostate Cancers)
Primary: Number of Participants With Bone Bio-marker Response — 13; 9; 8 Participants
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient